Rafferty Asset Management, LLC Vertex Pharmaceuticals Inc Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 86,309 shares of VRTX stock, worth $34.3 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

86,309

Previous 93,125 7.32%

Holding current value

$34.3 Million

Previous $43.6 Million 8.04%

% of portfolio

0.14%

Previous 0.16%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$460.0 - $505.78 $3.14 Million - $3.45 Million	-6,816 Reduced 7.32%	86,309 $40.1 Million
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $5.42 Million - $6.7 Million	13,809 Added 17.41%	93,125 $43.6 Million
Q1 2024 May 13, 2024	BUY	$407.69 - $446.08 $441,935 - $483,550	1,084 Added 1.39%	79,316 $33.2 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $411,600 - $492,816	1,200 Added 1.56%	78,232 $31.8 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $2.25 Million - $2.41 Million	6,650 Added 9.45%	77,032 $26.8 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $1.69 Million - $1.89 Million	5,361 Added 8.25%	70,382 $24.8 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $416,064 - $474,633	1,469 Added 2.31%	65,021 $20.5 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $583,236 - $656,140	2,041 Added 3.32%	63,552 $18.4 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $4.01 Million - $4.47 Million	14,629 Added 31.2%	61,511 $17.8 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $2.71 Million - $3.37 Million	-11,535 Reduced 19.75%	46,882 $13.2 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $881,694 - $1.04 Million	3,982 Added 7.32%	58,417 $15.2 Million
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $1.29 Million - $1.62 Million	7,270 Added 15.41%	54,435 $12 Million
Q3 2021 Nov 10, 2021	BUY	$181.39 - $202.99 $1.45 Million - $1.63 Million	8,019 Added 20.48%	47,165 $8.56 Million
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $288,172 - $339,830	1,537 Added 4.09%	39,146 $7.89 Million
Q1 2021 May 10, 2021	BUY	$207.02 - $241.31 $2.61 Million - $3.04 Million	12,588 Added 50.31%	37,609 $8.08 Million
Q4 2020 Feb 10, 2021	SELL	$207.01 - $276.09 $101,641 - $135,560	-491 Reduced 1.92%	25,021 $5.91 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $1.1 Million - $1.3 Million	4,286 Added 20.19%	25,512 $6.94 Million
Q2 2020 Aug 07, 2020	BUY	$225.48 - $295.8 $1.27 Million - $1.66 Million	5,611 Added 35.93%	21,226 $6.16 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $4.32 Million - $5.35 Million	-21,600 Reduced 58.04%	15,615 $3.72 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $2.4 Million - $3.23 Million	-14,405 Reduced 27.91%	37,215 $8.15 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $1.64 Million - $1.85 Million	9,885 Added 23.69%	51,620 $8.75 Million
Q2 2019 Aug 09, 2019	BUY	$164.61 - $190.37 $417,944 - $483,349	2,539 Added 6.48%	41,735 $7.65 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $4.85 Million - $5.76 Million	29,602 Added 308.55%	39,196 $7.21 Million
Q4 2018 Feb 11, 2019	SELL	$151.91 - $192.21 $219,661 - $277,935	-1,446 Reduced 13.1%	9,594 $1.59 Million
Q3 2018 Nov 09, 2018	BUY	$167.73 - $192.74 $7,883 - $9,058	47 Added 0.43%	11,040 $2.13 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $256,321 - $298,959	1,759 Added 19.05%	10,993 $1.87 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $130,830 - $152,863	-863 Reduced 8.55%	9,234 $1.51 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $672,809 - $762,350	-4,901 Reduced 32.68%	10,097 $1.51 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $2.22 Million - $2.43 Million	14,998	14,998 $2.28 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Vertex Pharmaceuticals Inc Transaction History